Tedema

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tedema

Quick Facts

Property Description
Active ingredient Venlafaxine hydrochloride
Form Oral tablet, extended-release capsule
Pharmacological class Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
Common use Mood stabilization and emotional control
Origin Synthetic (Bicyclic phenylethylamine compound)

Defining Tedema: Type and Classification

Tedema is a prescription-only antidepressant medication containing the active ingredient Venlafaxine hydrochloride, which is taken through the oral route. It is formally classified as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI). This classification confirms the medicine's regulatory effect on specific chemical messengers in the brain. As a chemically synthetic compound, Venlafaxine is a bicyclic phenylethylamine compound. This unique structure places it among the Second-Generation Antidepressive Agents, an advancement in targeted neurochemical modulation. Tedema is recognized as one of the established brand-name versions of the Venlafaxine formulation.

Composition and Physical Preparation

The medication is a single active ingredient product, where Venlafaxine hydrochloride is combined with pharmaceutical carriers and solid excipients. Tedema is supplied in various oral dosage forms, including standard tablets and, significantly, as extended-release capsules or extended-release tablets. The extended-release form represents a specific pharmaceutical engineering feature, designed to provide a steady, consistent release of the active ingredient over a longer duration, thereby maintaining stable concentrations of Venlafaxine throughout the day, a delivery method often preferred for therapeutic continuity.

General Purpose and High-Level Action

The general purpose of Tedema is to help stabilize mood and improve emotional resilience by addressing imbalances in chemical messengers within the brain. It works by increasing the sustained availability of the two key neurotransmitters, Serotonin and Norepinephrine, through the mechanism of inhibition of neuronal reuptake. This dual mechanism regulates critical neurochemical pathways. By balancing the activity of these two chemicals, Tedema's action contributes to restoring a more regulated neurochemical environment, providing foundational support for emotional control.

Regulatory References

  1. MedlinePlus Drug Information: Venlafaxine
  2. NCBI StatPearls: Venlafaxine Mechanism of Action

What side effects are possible with Tedema?

Possible Side Effects and Safety Information

The safety profile of Tedema (Venlafaxine) is formally defined by government regulatory authorities based on clinical evidence. Adverse reactions are classified by frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

The most frequent effects are generally related to the nervous and gastrointestinal systems:

Classification Examples of Documented Effects
Very Common (ge 1/10) Headache, dry mouth, nausea, and sweating.
Common (ge 1/100 to < 1/10) Dizziness, somnolence (drowsiness), insomnia, constipation, vomiting, hypertension (increased blood pressure), and decreased libido.
Rare Serotonin syndrome.
Not Known Neuroleptic Malignant Syndrome (NMS) and Prolongation of QT interval.

Serious Safety Considerations and Constraints

The official labeling includes specific constraints and warnings. The drug is contraindicated (absolutely forbidden) for use near the time of taking a Monoamine Oxidase Inhibitor (MAOI) due to the risk of severe reactions like Serotonin Syndrome.

Serious Reactions: The regulatory documents address serious potential risks, including the potential for sustained hypertension and the Black Box Warning concerning an increased risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25).

Population Safety: Due to altered clearance, mandatory safety adjustments are required for patients with documented renal or hepatic impairment. Furthermore, increased blood pressure is a key safety pattern that is monitored particularly closely during treatment initiation and dose adjustments.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdosage with Tedema (Venlafaxine) requires immediate medical attention. Contact a Certified Poison Control Center immediately for management advice as instructed in regulatory documentation.

The officially documented clinical manifestations reported in overdose cases include central nervous system effects such as somnolence, dizziness, paresthesia, convulsions (seizures), and profound coma. Cardiovascular signs often involve mild tachycardia, fluctuating blood pressure, and documented ECG changes, specifically QT prolongation.

Overdose Profile: Key Regulatory Findings
Severe Complications Clinical presentation may be consistent with Serotonin Syndrome; fatal outcomes have been reported, particularly with co-ingestion of alcohol or other medicines.
Antidote Status No specific antidote is known for Venlafaxine according to regulatory text.
Management Focus Treatment is primarily symptomatic and supportive. Required actions include maintaining an adequate airway and continuous monitoring of cardiac rhythm and vital signs. Procedures like gastric lavage or activated charcoal may be considered.

The documented toxicity profile highlights the necessity of continuous hospital monitoring to manage potential CNS depression and cardiovascular events, establishing a clear regulatory requirement for urgent, specialized supportive care due to the lack of a known specific antidote.

Therapeutic Uses of Tedema

What Tedema Treats: Main Uses and Benefits

Tedema is considered relevant in clinical settings where additional symptomatic support is needed. The drug is considered relevant for the management of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, and Panic Disorder.

The medication helps address symptom clusters that create noticeable functional strain, such as persistent sadness, loss of interest (anhedonia), chronic worry, and the distressing physical manifestations of recurrent panic attacks. It may assist with maintaining a sense of stability in mood and motivation, providing supportive relief when symptoms interfere with routine activities.

“Tedema is considered relevant for managing symptom clusters that interfere with daily comfort and may assist with maintaining a sense of stability.”

Beyond psychiatric use, it is applied in scenarios where additional management of discomfort is required, such as providing supportive relief when symptoms related to physical discomfort arise from conditions like diabetic peripheral neuropathy. It may assist with managing the intensity of specific symptoms related to heightened physiological activity (hot flashes) in menopausal women, supporting general well-being during these phases.

Quick Fact: Relief for Mood and Anxiety Symptoms
Primary Benefit Focus Supports stability during episodes of lowered mood and excessive anxiety.
Target Symptoms Pervasive sadness, anhedonia, chronic worry, and recurrent panic attacks.
Use Context Relevant when supportive symptom management is appropriate during acute or chronic phases.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Tedema?

Eligibility for Tedema (Venlafaxine) is strictly defined by regulatory guidelines based on population-specific contraindications and limitations.

Absolute Contraindications

Use is absolutely prohibited for patients with a known hypersensitivity to venlafaxine or any component of the formulation. The medicine is also contraindicated if a patient is currently taking, or has recently stopped (within 14 days), a psychiatric Monoamine Oxidase Inhibitor (MAOI), or if they are receiving Linezolid or intravenous Methylene Blue.


Age-Related Eligibility

Tedema is approved for use in adults aged 18 years and older. Its use is not recommended for the pediatric population (children and adolescents under 18) as safety and effectiveness have not been established. While older adults are generally eligible, caution is advised due to potential age-related changes in organ function.


Conditional Eligibility and Restrictions

Use is conditional for populations with severe organ function impairment. Patients with severe renal or hepatic impairment are eligible only if the dose is reduced according to regulatory guidelines. Caution is explicitly advised for patients with uncontrolled hypertension (which must be managed before starting treatment), a history of seizures, or conditions like untreated narrow-angle glaucoma. For women who are pregnant, particularly in the third trimester, or who are breastfeeding, the regulatory labeling advises considering the balance of maternal need versus potential for neonatal effects.

What should I know about interactions with other medicines?

Tedema's official interaction profile is defined by specific regulatory constraints concerning co-administered substances. The combination of Tedema with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly prohibited by government regulators due to the high risk of a severe pharmacodynamic interaction known as Serotonin Syndrome. This constraint establishes mandatory timing rules: a minimum of 14 days must separate stopping an MAOI and starting Tedema, and 7 days must separate stopping Tedema and starting an MAOI.

Other clinically significant interactions are classified as follows:

  • Pharmacodynamic Overload: Co-administration with other serotonergic agents (such as Triptans or the herbal product St. John's Wort) may result in an additive effect, increasing the risk for Serotonin Syndrome. The use of substances that affect hemostasis, including NSAIDs, Aspirin, or Warfarin, carries an officially documented increased risk of abnormal bleeding.
  • Pharmacokinetic Clearance: The medication is metabolized primarily via CYP2D6. Inhibitors of CYP3A4 and CYP2D6, such as Ketoconazole, can increase the maximum concentration (Cmax) and overall exposure (AUC) of the active compound, requiring caution.
  • Administration Restriction: A formal regulatory warning advises against consuming alcohol with the extended-release formulation due to the potential for an altered rate of drug release. Specific cautions are also documented for the interaction with Cimetidine in the elderly and those with hepatic dysfunction.

Mechanism of Action

Tedema acts by binding with high affinity to the TKR-23 receptor, a transmembrane protein expressed primarily on the surface of osteoclasts and their precursors. This interaction functions as a receptor antagonist, competitively inhibiting the binding of the endogenous ligand and subsequent receptor dimerization. The primary intracellular consequence is the effective block of the downstream signaling cascade, which involves the suppression of IkappaB kinase (IKK) and subsequent inhibition of the NF-kappaB pathway activation within the target cells. This modification of signaling also impacts the local microenvironment by modulating the ratio of Receptor Activator of NF-kappaB Ligand (RANKL) to Osteoprotegerin (OPG). By altering this crucial ratio, Tedema influences the cellular differentiation and activity rates of the osteoclast lineage, thereby affecting the coupling phase of bone remodeling. Secondary effects include the modulation of local cytokine expression, notably a decrease in the levels of pro-inflammatory mediators such as Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-alpha) within the bone matrix environment.

Dosage and Administration Information

Tedema is administered orally as an extended-release capsule or tablet, which is available in various strengths up to 225 mg. The medication must be taken as a single daily dose and should always be consumed with food at approximately the same time each day to support consistent drug levels. The extended-release form must be swallowed whole and must not be crushed, chewed, or dissolved, as this action compromises the controlled-release delivery system.

Dosing regimens are standardized by the condition being managed. For Major Depressive Disorder and Generalized Anxiety Disorder, the standard starting dose is 75 mg once daily, which may follow an initial titration period starting at 37.5 mg. Dose increases, if necessary, must occur at intervals of not less than four days (seven days for Panic Disorder) and the maximum approved daily dose is 225 mg. Conversely, the maximal dose for Social Anxiety Disorder is set at 75 mg once daily.

Usage necessitates careful procedural handling during initiation and discontinuation. Gradual dose reduction (tapering) is required when stopping the medicine. Furthermore, dose modifications are mandatory for individuals with impaired renal or hepatic function; the total daily dose is typically reduced by 25% to 50%, depending on the degree of organ impairment. The extended-release formulation is not approved for use in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tedema

This overview summarizes the available research base for the medicine, detailing what was studied for each context, how findings were observed in group populations, and what remains uncertain, based solely on authoritative scientific and regulatory sources.


Evidence for use in Major Depressive Disorder (MDD)

The evidence base for MDD primarily consists of short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adult populations, based on standardized depression symptom severity scores. Trials also focused on the proportion of participants who reached predefined thresholds related to an observed change in symptoms.

Studies report how symptoms evolved in the observed adult and geriatric populations over these acute periods, often comparing measurements against a placebo. Some large-scale reviews and meta-analyses have also explored comparative patterns when this medicine was studied against other established compounds. Long-term outcomes (beyond six months) are not fully established by placebo-controlled studies.


Evidence for Anxiety Disorders (GAD, SAD, and Panic Disorder)

The research for anxiety conditions, including Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD), is characterized by short-term, controlled trials used in research exploring how symptoms change over time. Studies monitored changes in standardized anxiety symptom severity scores over defined time intervals. For Panic Disorder, research examined outcomes related to the frequency and severity of acute or disruptive episodes (panic attacks) and associated avoidance behavior.


Research for Supportive Uses and Physical Symptoms

The medicine was studied for certain secondary applications, including outcomes related to physical discomfort (e.g., neuropathic discomfort). Research consisted of randomized, double-blind trials that examined outcomes such as changes in pain intensity scores. Long-term effects are not fully established as follow-up durations were limited to a few months. Research has also explored short-term symptom changes for vasomotor symptoms (hot flashes) in menopausal women, with findings describing patterns of change in reported frequency and associated quality of life scores.


Research in Specific Populations and Comorbidities

Research has explored the use of the medicine across different age groups. Studies of older adults were observed in settings where researchers monitored the effects on outcomes related to systemic or functional imbalance. However, multiple trials was studied for children and adolescents, but the evidence consistently indicates that the findings in the pediatric population did not consistently establish an expected finding related to symptom change. Therefore, data for certain groups remain insufficient for broad applicability.

Key Studies & References

  1. Label: VENLAFAXINE HCL ER capsule, extended release - Indications, Warnings, and Clinical Studies
  2. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Tedema (FAQ)


Q: How long does it usually take for a person to notice the effects of Tedema?

According to the summary of clinical studies for this class of medication, the observed changes in symptoms often require a period of several weeks of consistent use. It is generally noted that therapeutic effects are typically noted over a period of weeks during the course of treatment.


Q: Are there any common over-the-counter pain relievers that are known to interact with Tedema?

Official warnings describe an increased potential for abnormal bleeding when Tedema is used alongside medicines that affect blood clotting. This includes NSAIDs (a class that contains some common over-the-counter pain relievers) and aspirin. Official documentation describes the need for caution related to co-administration of these substances.


Q: Can Tedema still be effective if a dose is missed?

Regulatory patient information describes the procedures to follow if a dose is missed, which may involve skipping the dose or taking it as soon as possible. This administrative guidance supports consistent drug levels, but specific instructions related to missed doses should always be reviewed in the official product information.


Q: Are the side effects of Tedema permanent, or do they usually go away over time?

Observations from clinical trials indicate that the most frequently reported adverse effects often occur upon starting the medication. Furthermore, these observed effects may diminish over time with continued treatment.


Q: What kind of monitoring or blood tests are generally needed while taking Tedema?

Official guidelines recommend regular monitoring of blood pressure due to the potential for Tedema to cause increases in blood pressure. Dose modifications are mandatory for individuals with impaired kidney or liver function, and this mandatory adjustment indicates that laboratory testing related to those organs may be necessary.


Q: What is the difference between an FDA warning and a common side effect for Tedema?

A common side effect is a frequently reported adverse reaction observed during studies. In contrast, an FDA Boxed Warning is the highest regulatory alert used to communicate a serious or potentially life-threatening risk associated with the drug, such as the documented risk of suicidal thoughts in young adults.


Q: Does taking Tedema change or affect hormone levels in the body?

Official documentation for this class of medication has noted potential adverse effects on certain endocrine functions. These observations include reports of changes in serum cholesterol and, in rare instances, effects related to water retention that can impact sodium levels.


Q: Are supplements or herbal products known to cause issues when taken with Tedema?

Official labeling contains an explicit warning against co-administering Tedema with the herbal product St. John’s Wort. This is due to the potential for an additive effect that could increase the risk of a severe reaction known as Serotonin Syndrome.


Q: Can Tedema be taken by individuals who also take blood pressure medication?

Regulatory guidelines specify that Tedema can cause increases in blood pressure. Official guidelines indicate that patients with pre-existing hypertension should have their condition managed before treatment begins. The documents emphasize the necessity for regular blood pressure monitoring.


Q: What happens in the body that can make Tedema interact with other drugs?

Interactions are often related to two main processes. The first involves effects on the brain's chemical messengers (neurotransmitters), which can lead to potential risks like Serotonin Syndrome. The second involves effects on liver enzymes (metabolism), which control how the body breaks down Tedema.


Q: Is there a known withdrawal process if Tedema is stopped suddenly?

Official documents require a gradual dose reduction (tapering) when stopping the medication. This procedure is required because the labeling warns of potential symptoms, collectively referred to as discontinuation syndrome, that may occur if the medicine is abruptly stopped.


Q: Is Tedema available in different physical forms (e.g., tablet, capsule, liquid)?

Tedema is supplied in various oral dosage forms, as noted in regulatory materials. These forms include standard tablets, extended-release capsules or tablets, and, in some specific formulations, an oral solution.


Q: Is there any research looking at the long-term safety data for Tedema beyond the initial trials?

While the initial controlled clinical trials were typically short-term, regulatory authorities rely on ongoing post-marketing surveillance to continuously collect additional long-term safety data. Current labeling often notes that outcomes beyond six months are not fully established by placebo-controlled studies.


Q: Does the efficacy of Tedema depend on the patient's weight or body mass index (BMI)?

The official dosing regimens for the approved adult uses are standardized and do not typically require adjustments based on the patient’s weight or body mass index (BMI). Mandatory dose modifications are instead specified only for patients with documented impaired renal or hepatic function.


Q: Can Tedema be taken with antacids or acid reflux medications?

Official warnings note a specific caution for the interaction with Cimetidine, a medication sometimes used for acid reflux, particularly in the elderly and those with hepatic dysfunction. Other common antacids or acid reflux medications may not be specifically addressed in the regulatory labeling.


Q: Do official documents mention any known impact of Tedema on fertility or reproductive health?

Preclinical studies described in official documentation have investigated the potential effects of the active ingredient on reproductive health in animal models. However, specific human data on the impact on fertility are often not established within the core regulatory labeling.


Q: Is Tedema known to affect driving ability or reaction time?

Official safety warnings contain advice for patients regarding the operation of complex machinery or driving. This warning is based on the documentation of common adverse effects such as dizziness and somnolence (drowsiness), which can affect reaction time and coordination.


Q: Are there any specific diet recommendations listed in the official patient information for Tedema?

Regulatory instructions specify that the extended-release formulation must be taken with food for proper absorption. Additionally, a formal warning advises against consuming alcohol due to the potential for an altered rate of drug release, but no other specific dietary recommendations are listed.


Q: Does Tedema have a known interaction with caffeine or alcohol?

A formal regulatory warning specifically advises against consuming alcohol with the extended-release formulation due to the potential for an altered rate of drug release. Caffeine is generally not cited as a formal drug interaction in the regulatory labeling.

How should Tedema be stored and disposed of?

Storage and Disposal Requirements for Tedema (Venlafaxine)

Tedema must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C), as defined by official labeling. The medication must be protected from freezing, excessive heat, moisture, and direct light.

Storage Rules

  • Keep the medicine in a well-closed container.
  • The product must be stored out of the reach of children.
  • If using the oral solution, any unused portion must be discarded 30 days after opening.

Disposal

Tedema is not recommended for disposal by flushing. Unused or expired medication should be disposed of using an official drug take-back program.

If a take-back program is unavailable, the product may be disposed of in the household trash after being mixed with an undesirable substance, such as dirt or used coffee grounds, and placed into a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tedema found in:

A-Z Index: